Analysis of the effects of exposure to acute hypoxia on oxidative lesions and tumour progression in a transgenic mouse breast cancer model by Kalliomäki, Tuula M et al.
BioMed  Central
Page 1 of 13
(page number not for citation purposes)
BMC Cancer
Open Access Research article
Analysis of the effects of exposure to acute hypoxia on oxidative 
lesions and tumour progression in a transgenic mouse breast cancer 
model
Tuula M Kalliomäki1,2, Gordon McCallum4, Sarah Jane Lunt1,2, 
Peter G Wells4 and Richard P Hill*1,2,3
Address: 1Applied Molecular Oncology Division, Ontario Cancer Institute/Princess Margaret Hospital, Canada, 2Department of Medical 
Biophysics, University of Toronto, 610 University Avenue, Toronto, Ontario, M5G 2M9, Canada, 3Radiation Oncology, University of Toronto, 610 
University Avenue, Toronto, Ontario, M5G 2M9, Canada and 4Department of Pharmaceutical Sciences, University of Toronto, 144 College Street, 
Toronto, Ontario, M5S 3M2, Canada
Email: Tuula M Kalliomäki - tuula.kalliomaki@gmail.com; Gordon McCallum - gordon.mccallum@utoronto.ca; 
Sarah Jane Lunt - sarahjanerutherford@gmail.com; Peter G Wells - pg.wells@utoronto.ca; Richard P Hill* - hill@uhnres.utoronto.ca
* Corresponding author    
Abstract
Background: Tumour hypoxia is known to be a poor prognostic indicator, predictive of increased
risk of metastatic disease and reduced survival. Genomic instability has been proposed as one of
the potential mechanisms for hypoxic tumour progression. Both of these features are commonly
found in many cancer types, but their relationship and association with tumour progression has not
been examined in the same model.
Methods: To address this issue, we determined the effects of 6 week in vivo acute hypoxic
exposure on the levels of mutagenic lipid peroxidation product, malondialdehyde, and 8-oxo-7,8-
dihydro-2'-deoxyguanosine DNA (8-oxo-dG) lesions in the transgenic polyomavirus middle T
(PyMT) breast cancer mouse model.
Results: We observed significantly increased plasma lipid peroxidation and 8-oxo-dG lesion levels
in the hypoxia-exposed mice. Consumption of malondialdehyde also induced a significant increase
in the PyMT tumour DNA lesion levels, however, these increases did not translate into enhanced
tumour progression. We further showed that the in vivo exposure to acute hypoxia induced
accumulation of F4/80 positive tumour-associated macrophages (TAMs), demonstrating a
relationship between hypoxia and macrophages in an experimental model.
Conclusion: These data suggest that although exposure to acute hypoxia causes an increase in 8-
oxo-dG lesions and TAMs in the PyMT tumours, these increases do not translate into significant
changes in tumour progression at the primary or metastatic levels in this strong viral oncogene-
driven breast cancer model.
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Background
Hypoxia in tumours is a predictor of poor patient survival.
This has been shown most extensively in soft tissue sar-
coma, and in cervical and head and neck carcinoma
patients where tumour hypoxia, as assessed by partial
pressure of oxygen (pO2) measurements, is predictive of
metastatic and/or disease-free survival [1]. In breast cancer
patients the role of hypoxia as a predictor for survival has
been demonstrated through immunohistochemical detec-
tion of hypoxia-dependent markers, such as hypoxia-
inducible factor-1α (HIF-1α) and carbonic anhydrase IX
(CAIX) [2,3].
The underlying mechanisms for hypoxia-mediated
tumour progression are not well understood. Examina-
tions of the effects of different types of tumour hypoxia on
metastatic progression have suggested acute (cycling)
hypoxia to be more important than chronic (diffusion
limited) hypoxia [4,5]. A potential association between
acute hypoxia and genomic instability has been suggested
by Comet assay data, which showed significantly
increased numbers of single-strand DNA breaks in
tumour samples from mice exposed to acute hypoxia
compared with samples from mice exposed to chronic
hypoxia (Cairns and Hill, unpublished data, 2004). Simi-
lar data has been reported in tumour cells exposed to
increased number of hypoxic cycles in vitro, which
resulted in increased number of DNA mutations, the fre-
quency and types of which resembled those found in the
same cells grown as tumours in vivo [6]. In vitro hypoxia
exposure can also mediate larger scale genomic instability
by increasing fragile site induction, gene amplification
and cellular DNA content [7-9].
In some cases genomic instabilities in hypoxic tumours
have been attributed to hypoxia-mediated inhibition of
various DNA repair mediators from the homologous
recombination, mismatch repair and non-homologous
end joining DNA repair pathways [10-13]. However, the
role of reactive oxygen and nitrogen species (ROS, RNS) in
tumour progression as mediators of a "mutator pheno-
type" is also well documented [14,15] and acute hypoxia
is known to generate these species through multiple sys-
tems including mitochondria, xanthine oxidase, ferrylhe-
moglobin, NADPH oxidase and thymidine
phosphorylase [16,17]. Upon reaction with DNA, free
radicals can generate mutagenic DNA lesions, such as 8-
oxo-dG, that cause GC→TA transversions and structural
changes compromising the transcriptional fidelity of the
genome [18]. DNA damage can also be induced indirectly
through free radical reaction with polyunsaturated fatty
acids of cellular membranes and formation of lipid perox-
idation products such as, isoprostanes, 4-hydroxynonenal
and malondialdehyde (MDA), shown to induce frame-
shift mutations and base pair substitutions [19,20].
Macrophages (MØs), which have been reported to be
attracted to hypoxic tumour areas, are also a source of
mutagenic superoxide (O2
-), nitric oxide (NO) and perox-
ynitrite (ONOO-) species [21,22]. In tumours, the MØs
can promote tumour cell angiogenesis, invasion and sur-
vival by up-regulating genes such as GLUT-1, VEGF,
CXCR4 and MIF [23] and high levels of these tumour-
associated macrophages (TAMs) can predict poor patient
survival [24]. In support of the concept of TAM-mediated
tumour progression, Pollard and colleagues showed that
reducing the number of TAMs in the polyoma middle T
(PyMT) breast cancer model by crossing it to op/op null
mice with a mutation in the colony stimulating factor-1
(CSF-1) gene, inhibited metastasis formation [25]. Fur-
ther studies in the same model demonstrated that tumour
cell movement and intravasation occur most frequently
when the tumour cells are within 20 μm of a perivascular
TAM [26].
In this study we examined the effect of acute (cyclic)
hypoxia on tumour progression in relation to oxidative
stress, TAMs and genomic instability in the MMTV-PyMT
model. We demonstrated significantly increased levels of
8-oxo-dG lesions and TAM content in tumours from mice
exposed to acute hypoxia but these increases did not
translate into significant changes in tumour progression.
Methods
Animals
A breeder pair of mice with a PyMT transgene under the
MMTV promoter (MMTV-PyMT634Mul), originally
described by Guy et al., was obtained from Dr. Rama
Khokha (Princess Margaret Hospital, Ontario Cancer
Institute, Toronto, Canada) [27]. The mice were bred and
maintained at the Animal Resource Centre of the Ontario
Cancer Institute in compliance with the guidelines of the
Canadian Council on Animal Care. Tissue samples were
obtained at 2 weeks-of-age and screened for the presence
of the PyMT transgene using the following primers (for-
ward) 5' GGA AGC AAG TAC TTC ACA AGG 3' and
(reverse) 5' GGA AAG TCA CTA GGA GCA GGG 3'. Mice
were weaned at 3 weeks-of-age. All experiments were con-
ducted with heterogeneous, virgin MMTV-PyMT or litter-
mate wild type (WT) mice.
Hypoxia, malondialdehyde and 2-nitropropane 
treatments
For acute hypoxia (AH) experiments, mice were treated 5
times a week for 6 weeks, from 3 to 9 weeks-of-age. The
hypoxia exposure consisted of 12 cycles of 10 min of air,
followed by 10 min of 7% oxygen, balance nitrogen for a
daily total of 4 hours, in airtight chambers as described
previously [4]. Air control (AC) animals were exposed to
a daily total of 4 hours of air in separate sealed chambers
and cage control (CC) animals were left in their cagesBMC Cancer 2008, 8:151 http://www.biomedcentral.com/1471-2407/8/151
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untouched. For HPLC and immunohistochemical analy-
ses, mice were killed within 1 hour following the last gas-
sing exposure at the age of 9 weeks to ensure similar
tumour development for mammary tissues from mice
treated for 4 hours/day during 1 day, 5 days or 6 weeks.
For the tumour progression studies, the mice were left in
their cages following the 6-week exposure until they
reached the age of 88 days at which time the experiment
was terminated and primary tumour growth and metas-
tases were assessed. For determination of tumour hypoxia
levels, mice were injected intraperitoneally (10 mM, 0.01
mL/g) with the exogenous hypoxia marker, EF5 ([2-(2-
nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl
acetamide], Dr. Cameron Koch, University of Pennsylva-
nia), 1 hour into the 4 hour gassing exposure during a
reoxygenation cycle and killed within 1 hour of the last
hypoxic cycle.
Animals treated with the lipid peroxidation product,
malondialdehyde, (MDA, Sigma-Aldrich) received acidi-
fied water with 10 mM MDA, replaced twice a week while
control animals (MDA-CC) received normal acidified
water. The drug concentration was based on a measured
average daily water consumption of 3.75 mL/mouse/day
and calculated to give an approximate daily dose of 250
mg/kg [28]. Mice received the treated water for 6 weeks,
from 4 to 10 weeks-of age at which point they were killed
if used for HPLC analysis or left to develop their tumours
to the age of 81 days if used for tumour progression anal-
ysis. An oxidizing agent, 2-nitropropane (2-NP, Sigma-
Aldrich), reported to increase the number of 8-oxo-dG
lesions in mice, was used as a positive control for the
HPLC analyses [29]. It was administered intraperitoneally
at 167 mg/kg in sterile olive oil vehicle and the mice were
sacrificed 24 hours after a single dose at the age of 81 days.
Immunohistochemistry (IHC)
Snap frozen tumour tissue from hypoxia-exposed mice
was used for IHC staining of markers for macrophages
(F4/80; ab6640: 1/300 1 hr R/T; Abcam Inc., Cambridge,
MA), base excision repair (APE/Ref-1; ab82: 1/100 O/N
4°C; Abcam Inc., Cambridge, MA), hypoxia (EF5; ELK3-
51: 1/50 O/N R/T; Dr. Cameron Koch, University of Penn-
sylvania) and vasculature (CD31; MEC13.3: 1/500 1 hr R/
T; BD Pharmingen) according to manufacturer's instruc-
tions. Total area of positive staining in tumour sections, (1
per tumour, of approximately 43 mm2) with areas of
necrosis and connective tissue excluded, was quantified
with the positive pixel algorithm by Aperio ImageScope
(Aperio Technologies, Vista, CA). Inter-mouse variability
of EF5 staining was quantified in 31 tumours from 11 dif-
ferent mice.
Assessment of primary and metastatic tumour burdens
In AH experiments primary tumour burden and the
number of lung metastases were determined in 88-day-
old mice. This time was reduced by a week to 81 days for
MDA experiments to reduce the tumour burden prior to
sacrifice since the MMTV-PyMT mice develop multiple
primary tumours. The primary tumour burden was
obtained by multiplying tumour length × tumour width
and summing the individual tumour values of each
mouse. Lungs were fixed in 10% neutral buffered forma-
lin for 48 hours and then transferred to 70% ethanol.
Macroscopic lung metastases in individual lung lobes
were scored under a dissecting microscope. Micrometas-
tases in each pair of lungs were summed from 4 sections
(separated by 100 μm) stained with haematoxylin and
eosin (H+E).
Lipid peroxidation (TBARS) and antioxidant reductive 
capacity assays
Heparinized blood from hypoxia- and control-exposed
mice was centrifuged at 6000 rpm for 1 min. The sepa-
rated plasma was divided into 2 aliquots to prevent
repeated freezing and thawing of the sample and stored at
-80°C until analysis. Plasma samples were analysed with
the thiobarbituric acid reactive substance (TBARS) assay,
which measures MDA by reaction with thiobarbituric acid
to form a red product that was quantified spectrophoto-
metrically. MDA was quantified in 150 μL of plasma with
5  μl of 0.1 M butylated hydroxytoluene (BHT, Sigma-
Aldrich). Following the addition of 62.5 μL of pure glacial
acetic acid and 62.5 μL of 0.67% thiobarbituric acid
(Sigma-Aldrich), the samples were incubated at 50°C for
2 hours and cooled to room temperature for extraction of
the coloured reaction product with 1 mL of 1-butanol,
which was read with a spectrophotometer at 535 nm [30].
The antioxidant status of the plasma from AH and AC
exposed mice was assayed with an antioxidant reductive
capacity assay (NWK-ARC01; Northwest Life Science Spe-
cialties, Vancouver, WA). This 96-well assay is based on
the ability of sample antioxidants to reduce Cu++ to Cu+,
which reacts with bathocuproine to form a coloured prod-
uct, read at 492 nm. Plasma samples from 10–11 mice
were assayed in triplicate.
Quantification of 8-oxo-7,8-dihydro-2'-deoxyguanosine 
lesions in DNA
DNA isolation and purification
The DNA extraction protocol was based on work pub-
lished by Ravanat et al. [31]. Briefly, the snap frozen
tumour samples were thawed on ice, homogenized with 1
mL of lysis buffer A (10 mM Tris-HCl, 320 mM sucrose, 5
mM MgCl2, 0.1 mM desferroxamine, 1% Triton X-100, pH
7.5) and centrifuged at 1,000 g for 10 min to isolate the
nuclear pellet. The pellet was washed once in lysis bufferBMC Cancer 2008, 8:151 http://www.biomedcentral.com/1471-2407/8/151
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A and resuspended into 200 μL of buffer B (10 mM Tris-
HCl, 1% w/v SDS, 5 mM EDTA-NA2, 0.15 mM desferrox-
amine, pH 8.0) using a plastic Kontes Pellet Pestle®. RNA
was digested by adding 13.3 μl of a 50 U/mL RNase A and
100 U/mL RNase T solutions for 1 hr at 50°C. A protein-
ase K solution (13.3 μl; 5 mg/mL) in 10 mM Tris/1 mM
EDTA, pH 7.4 was added for protein digestion at the same
incubation conditions. Prior to the DNA extraction, the
samples were centrifuged at 10,000 g for 10 min to
remove any undigested tissue. DNA was precipitated with
0.3 mL of Buffer C (40 mM Tris-HCl, 7.6 M NaI, 20 mM
EDTA-NA2, 0.3 mM desferroxamine, pH 8.0) and 0.5 mL
of 100% isopropanol. The precipitate was centrifuged at
10,000 g and washed 4 times with 70% ethanol. The DNA
pellet was resuspended in 20 mM Na-acetate buffer with
0.1 mM desferroxamine, pH 5.2. Diluted DNA samples
were digested with 5 U of nuclease P1 prepared in 20 mM
Na-acetate buffer. The pH was adjusted to 8.5 with 1 M
Tris-HCl buffer and the DNA hydrolyzed to nucleosides
by incubation with 6 U of calf intestine alkaline phos-
phatase (Roche Diagnostics, Laval, PQ) for 1 hr at 37°C.
The suspension was transferred to Microcon® YM-10 spin
columns (Millipore, Mississauga, ON) and centrifuged at
10,000 g for 30 min, filter-sterilized and injected for
HPLC analysis.
HPLC conditions
The HPLC system (200 series, Perkin Elmer, Woodbridge,
ON) consisted of a 0.2 μm mobile phase filter, a vacuum
degasser, an isocratic HPLC pump set at 1.0 mL/min, an
autosampler with a 200 μL sample loop and a Spherisorb®
ODS-2 guard column (10 × 4.6 mm i.d., 5 μm, Waters,
Mississauga, ON), and 2 Spherisorb® ODS-2 analytical
columns (150 × 4.6 mm i.d., 5 μm, Waters, Mississauga,
ON) connected in series. The mobile phase consisted of
7.5% methanol, and 50 mM sodium phosphate buffer,
pH 5.5, filtered through a 0.2 μm filter (Millipore, Missis-
sauga, ON). The 8-oxo-dG was detected with an electro-
chemical detector (Coulochem II 5200A, ESA,
Chelmsford, MA) with a PEEK-filter protected analytical
cell (5010, ESA; 10nA; screen electrode +100 mV; analytic
electrode, +400 mV). The dG was detected with a UV
detector (200 series, Perkin Elmer, Woodbridge, ON) set
at 280 nm. Data were recorded using a NCI 902 dual
detector interface and analyzed with Totalchrom Worksta-
tion Ver 6.3.1 software (Perkin Elmer, Woodbridge, ON).
Levels of 8-oxo-dG and dG in samples were quantified via
calibration curves with authentic standards.
Statistical analysis
For non-parametric data sets, such as those for metastases,
the Kruskal-Wallis test with Dunn's correction for multi-
ple comparisons was performed on experiments with 3 or
more groups and the Mann-Whitney test was performed
on experiments with 2 groups. For parametric data sets
with equal variances, such as those for tumour burden,
ANOVA with Bonferroni correction was performed on
experiments with 3 or more groups and Student's t-test
was performed on experiments with 2 groups. Mixed
modelling was used to correct for inter-experimental vari-
ability in repeat TBARS assays.
Results
Lowering of tumour oxygenation with in vivo acute 
hypoxia gassing regime
The hypoxia marker EF5 was used to identify hypoxic
areas in the MMTV-PyMT tumours (Figure 1A). Although
the overall values of EF5 positive areas were relatively low,
the total median EF5 positive area was significantly
greater in tumours from mice exposed to 6 weeks of AH
than AC gassing (Figure 1B; P < 0.05). Interestingly, inter-
tumour variability in EF5 positive areas of individual ani-
mals was substantial, varying from 0.3% to 8.1% per
mouse.
Oxidative stress and genomic instability in hypoxia- and 
MDA-treated mice
To determine the extent of oxidative stress induced by the
gassing, plasma was obtained from transgenic and WT
mice following the 6-week gassing regime. Mean plasma
TBARS levels were greater in mice exposed to AH than in
animals exposed to AC in 3 separate experiments, a differ-
ence that was shown to be significant with mixed model-
ling analysis (P < 0.0005). TBARS levels in mice drinking
MDA-supplemented water were also significantly
increased relative to both gassing groups (Table 1). Oxida-
tive stress was also assessed by HPLC quantification of 8-
oxo-dG lesions. Tumour samples from mice exposed to
AH showed an increasing difference relative to AC mice
over the 1 day, 5 day and 6 week exposures. The difference
was significant by the 6 week time point (P < 0.05). MDA
consumption increased tumour 8-oxo-dG lesions signifi-
cantly at all time points (Figure 2).
Effects of acute hypoxia and MDA on primary and 
metastatic tumour progression
To address the question on how MDA or hypoxia would
affect tumour progression of the MMTV-PyMT model, pri-
mary and metastatic tumour burdens were quantified in
mice exposed to these conditions. MDA consumption,
which resulted in a significant increase in 8-oxo-dG lesion
levels, did not significantly alter any of the tumour pro-
gression parameters examined (Figures 3A–C). The pri-
mary tumour burden following AH exposure also
remained unaffected relative to AC mice, although both
AC and AH groups had significantly reduced primary
tumour burdens relative to unexposed CC mice (Figure
3A). The numbers of macroscopic metastases showed the
same range and no significant differences between the AC,
AH and CC groups (Figure 3B).BMC Cancer 2008, 8:151 http://www.biomedcentral.com/1471-2407/8/151
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Total antioxidant capacity and APE/Ref-1 levels in 
hypoxia treated mice
To determine whether altered antioxidant levels in AH
exposed mice may have been the underlying reason for
the small increase in 8-oxo-dG lesions, the total antioxi-
dant capacity of plasma from the AC and AH mice was
assessed. Plasma from AH-exposed mice showed a trend
of reduced antioxidant reductive capacity relative to
plasma from AC mice (Figure 4A; P = 0.0667). Assessment
of the relationship between plasma antioxidant capacity
and tumour 8-oxo-dG lesions revealed a significant corre-
lation between these parameters in the AC group (Figure
4B; r2 = 0.9094, P < 0.05), which did not occur with the
hypoxia exposure.
APE/Ref-1 is a multifunctional protein that acts as an
endonuclease in the BER pathway and controls the activ-
ity of transcription factors, such as AP-1 and HIF-1α by
regulating their state of oxidation. Cellular localization of
APE/Ref-1 is generally found to be ubiquitous, but varying
between nuclear and cytoplasmic compartments [32].
APE/Ref-1 staining in the MMTV-PyMT tumours was pri-
Levels of EF5 following 4 hours of in vivo acute hypoxia exposure Figure 1
Levels of EF5 following 4 hours of in vivo acute hypoxia exposure. (A) An H+E stained tumour section from a PyMT 
mouse tumour with EF5 positive hypoxic areas stained in brown, necrotic tumour core is marked with an asterix. Scale bar: 
100 μm. (B) Quantification of total EF5 positive staining area (%) in 31 tumours from 11 PyMT mice exposed to AC or AH 
conditions for 4 hours showed significantly greater median levels of hypoxia in mice exposed to AH than in mice exposed to 
AC (P < 0.05; *).
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Table 1: TBARS plasma lipid peroxidation levels following oxidative stresses
Absorbance values (Arbitrary scale)
Air Control (AC) Acute Hypoxia (AH) Ratio (AH/AC) MDA treatment
Expt 1 (n = 4–5) 0.080+/-0.005 0.101+/-0.007 1.27 0.519+/-0.066
Expt 2 (n = 7) 0.132+/-0.006 0.152+/-0.008 1.16
Expt 3 (n = 8–9) 0.048+/-0.002 0.060+/-0.004 1.24
Lipid peroxidation assessed by TBARS assay in plasma of transgenic mice treated with 6 weeks of acute hypoxia (AH) showed a significantly 
increased plasma absorbance levels relative to air control (AC) conditions in 3 repeat assays (mixed modelling analysis on combined data; P < 
0.0005). Lipid peroxidation in plasma of positive control WT animals drinking MDA-supplemented acidified water for 6 weeks was significantly 
increased relative to both AH – (P < 0.01) and AC – (P < 0.001) exposed mice. Mean+/- SEM are shown for each experimental group.BMC Cancer 2008, 8:151 http://www.biomedcentral.com/1471-2407/8/151
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marily localized to the connective tissue (Figure 4C). In
tumour cells, the staining levels were generally low and
primarily cytoplasmic and were not found to differ
between the two treatment groups. Image analysis was
conducted in tumour tissues only and in tumour with
connective tissue included, but neither analysis showed a
difference between AH- and AC-exposed mice (Figure
4D).
Effects of hypoxia on TAMs and vasculature
TAMs have been previously reported to be involved in
tumour progression in the MMTV-PyMT model and to
accumulate in hypoxic areas [21,25,26]. To quantify TAM
content, tumour samples were stained with the MØ
marker F4/80. Interestingly, the F4/80 positive staining
was seen evenly throughout the tumours in contrast to the
highly localized staining pattern commonly seen with
extrinsic hypoxia markers such as EF5 (cf. Figures 1A and
5A). The overall levels of F4/80 were significantly
increased in samples from hypoxia-relative to air-exposed
mice (Figure 5B; P < 0.05). TAMs have been reported to
have pro-angiogenic effects [33,34] and therefore tumour
vasculature was quantified through CD31 staining (Figure
5C). Similarly to our previous in vivo acute hypoxia study
in a cervical tumour model the total area of CD31 positive
staining was significantly reduced following AH exposure
despite the increase in TAMs [35] (Figure 5D; P < 0.01).
Discussion
Hypoxia has been reported to enhance metastatic tumour
progression and to be associated with oxidative stress,
genomic instability and TAMs [21,36-38]. We have previ-
ously shown metastasis-promoting effects of in vivo acute
hypoxia in a murine fibrosarcoma and a human ortho-
topic cervical model [4,35] and in the current study, we
examined the relationships between the above parameters
in an in vivo transgenic breast cancer model with high met-
astatic potential.
In human breast cancer, the mutagenic end product of
lipid peroxidation, MDA, is commonly used as a marker
for oxidative stress [19,39], which in turn has been associ-
ated with induction of epithelial cell invasiveness and
metastatic phenotype [40,41]. In our study, TBARS assay
of plasma for lipid peroxidation products from mice
exposed to AH shows a significant increase relative to AC
mice. The increased level of oxidative stress following AH
exposure was further supported by the trend of reduced
Tumour 8-oxo-dG lesion levels following oxidative stresses Figure 2
Tumour 8-oxo-dG lesion levels following oxidative stresses. Mutagenic 8-oxo-dG lesions quantified at 1 day time point 
resulted in significant changes between MDA and AH and MDA and C (P < 0.001; ***) groups. Following 6 weeks of treatment 
the lesion levels were significantly increased in AH mice relative to AC mice (P < 0.05; *). Legends: MDA = malondialdehyde; 
AH = acute hypoxia; C = pooled controls from air control and PBS injected groups; 2-NP = positive control, 2-nitropropane; 
CC = cage control. Bars: mean with SEM. Number of tumours used for each group is indicated below the bars.
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Primary and metastatic tumour progression in MDA- and AH – exposed mice Figure 3
Primary and metastatic tumour progression in MDA- and AH – exposed mice. (A) CC mice developed significantly 
larger primary tumours than mice exposed to AH (P < 0.001; ***) or AC conditions (P < 0.01; **). Six-week exposure to MDA 
did not affect the size of endpoint tumour burden relative to MDA-CC. (B) MDA or AH exposure during primary tumour 
development did not increase macroscopic lung metastases relative to their respective controls. (C) A trend towards an 
increased number of micrometastases was seen following MDA consumption. Micrometastases were not assessed in the 
hypoxia experiment due to a large number of macroscopic metastases. Abbreviations: MDA = malondialdehyde (n = 28) and 
MDA-CC = cage controls for MDA group (n = 30), 81 days; AH = acute hypoxia (n = 24), AC = air control (n = 26) and CC = 
cage controls for AH group (n = 20), 88 days. Bars: mean with SEM (A), medians (B and C). Number of animals used for each 
group is indicated in parentheses.
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Total plasma antioxidant capacity and tumour APE/Ref-1 expression Figure 4
Total plasma antioxidant capacity and tumour APE/Ref-1 expression. (A) Plasma samples from mice exposed to AH 
showed a trend of reduced levels of total antioxidant reductive capacity relative to AC mice. (B) Scatter plot of total antioxi-
dant reductive capacity and 8-oxo-dG lesions in matching samples showed a significant positive correlation for AC mice (r2 = 
0.9094; P < 0.05), which was absent in the AH samples (r2 = 0.008383; P = 0.8836). (C) BER protein, APE/Ref-1 was expressed 
predominantly in the connective tissue of the MMTV-PyMT tumours. (D) Total positive staining area for APE/Ref-1 in tumour 
tissue (excluding connective tissue) did not differ in tissues from acute hypoxia and air control exposed mice. Bars: median 
with interquartile range. Scale bar: 50 μm.
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Quantification of TAM and vascular markers Figure 5
Quantification of TAM and vascular markers. (A) Representative cytoplasmic expression of MØ marker F4/80 in a 
MMTV-PyMT tumour section. (B) Total positive staining area of F4/80 was significantly higher in AH than AC treated animals 
(P < 0.05; *). (C) Representative staining pattern of vascular marker CD31 in MMTV-PyMT tumours. (D) Total CD31 positive 
area was significantly reduced following hypoxia exposure (P < 0.01; **). AH = acute hypoxia, AC = air control. Bars: mean 
with SEM. Scale bars: 50 μm.
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total antioxidant capacity in the plasma of AH-exposed
mice. The effects of increased oxidative stress in the
hypoxia-exposed (and in the MDA-fed) animals were also
quantified through HPLC analysis of 8-oxo-dG lesions.
These lesions are known to induce GC→TA transversions
[18] and have been previously used as a measure of oxida-
tive stress induced by hypoxia and as a marker of oxidative
stress in breast cancer patients [38,42]. Our HPLC analy-
ses of breast tumour tissue were consistent with the results
of the TBARS and antioxidant assays and showed greater
numbers of 8-oxo-dG lesions following AH exposure and
MDA consumption. We chose to quantify 8-oxo-dG
lesions based on their ROS-dependent formation and
their ability to induce mutations [18,43]. Therefore, one
of our underlying assumptions was that increased 8-oxo-
dG lesion levels would provide a general indication of
potential DNA lesions and hence mutagenic events asso-
ciated with oxic stress. An alternate approach might have
been to quantify specific, tumourigenesis-modifying
mutations such as base pair mutations, gene amplifica-
tions, chromosomal translocations or aneuploidy directly
from tumour biopsies, which would allow comparison of
mutation levels with tumourigenesis data on an individ-
ual animal basis. However, identifying which are the crit-
ical lesions is problematic and the relevant lesions might
be different in different tumours in the same animal, com-
plicating the analysis.
Together, our results provide in vivo evidence that the
cyclic hypoxia-breathing regime causes significant oxida-
tive stress and might be expected to induce genomic insta-
bility and tumour progression. However, despite the
increase in oxidative stress we observed little change in
tumour progression, although both gassing exposures did
significantly reduce primary tumour burdens relative to
cage control mice. This is likely due to various extra stres-
sors in the gassed mice such as handling, temporary (4 hr)
absence of food and water and exposure to foreign cage
mates, conditions that have all been reported to have the
potential to modify tumour progression [44-46]. Some of
the suggested underlying mechanisms include stressor-
mediated changes in various immune cell and cytokine
levels, accelerated telomere shortening and apoptosis
induction [46-48].
Although the increases in hypoxia-induced lipid peroxida-
tion and 8-oxo-dG lesions were statistically significant,
our data suggests that these changes may not have been
large enough to induce a biological impact. Therefore, we
treated animals with MDA, which induced greater
increases in 8-oxo-dG lesions than those seen with the AH
exposure, and assessed the animals for primary and meta-
static tumour progression. Despite the significant increase
in 8-oxo-dG lesions in MDA-fed mice, again no respective
changes in tumour progression were observed. These find-
ings suggest that increases in oxidative stress and 8-oxo-
dG lesions do not play a significant role in the tumour
progression of the MMTV-PyMT model. Similar conclu-
sions have also been reported from experiments with the
MMTV-PyMT model where the lack of a significant differ-
ence in point mutations between normal, malignant and
metastatic tissues and the lack of loss of heterozygosity
(LOH) above background levels was attributed to the
strong transforming ability of the middle T oncogene
[49,50]. This is consistent with the findings that several
pathological conditions with increased 8-oxo-dG levels in
tissue can occur without tumour incidence and studies
that have reported no relationship between DNA adduct
levels or even megabase deletions and cancer incidence
[51,52]. Furthermore, the mouse model deficient in
OGG1, a glycosylase responsible for removal of 8-oxo-dG
lesions, fails to demonstrate a significant effect on
tumourigenesis despite significantly elevated 8-oxo-dG
lesions [53,54]. A similar observation has been reported
for another glycosylase, MYH, and only when the two
mutants are combined or another stressor, such as UV
exposure, is introduced is an increase in tumour incidence
observed [55,56]. Therefore, it is possible that similar
compensatory mechanisms could have prevented the
hypoxia exposures from translating into changes in
tumour progression and that different results could be
seen if the gassings were imposed on one of the above-
mentioned repair-deficient models. Overall, our findings
are consistent with the idea that any effect of oxidative
stress on tumour progression in the MMTV-PyMT model
would require stress levels, which are not inducible by the
degrees of cyclic hypoxia or MDA exposures used in this
study, and emphasize the importance of the lesion type,
location and context in addition to their number.
The 6-week acute hypoxia exposure also resulted in a sig-
nificant increase in TAMs as detected by the F4/80 MØ
marker. TAMs are thought to represent a distinct MØ pop-
ulation, for which phenotypic characterization remains
incomplete. They differ in their activity from the MØ pop-
ulations found in normal tissues and their differentiation
depends on the cytokines expressed in the host tumour
[57]. Previous work has implicated a multitude of roles
for TAMs in tumour progression, including angiogenesis
and stimulation of cellular metastasis and survival
[23,58]. Our data show in vivo evidence of hypoxia-medi-
ated TAM accumulation to tumours, independent of ang-
iogenesis. Although discordances between hypoxia and
stimulation of angiogenesis have been reported previ-
ously, the absence of increased angiogenesis with increas-
ing TAM content seems to be in contrast to previous
reports [26,59]. This dissimilarity may be due to the dif-
ferent markers used for angiogenic quantification or vary-
ing angiogenic potentials between hypoxia- and CSF-1-
stimulated TAMs. Although the hypoxia-mediatedBMC Cancer 2008, 8:151 http://www.biomedcentral.com/1471-2407/8/151
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increase in F4/80 positive MØs did not translate into
increased tumour burden or lung metastases in the
MMTV-PyMT model, the lack of specific TAM co-localiza-
tion to hypoxic areas is consistent with previous observa-
tions in the MMTV-PyMT model where no co-localization
of TAMs to hypoxic areas, as identified through pimonida-
zole staining, was observed [34]. In future work, the AH
gassing exposure could be shifted from the period of pri-
mary tumour growth to metastasis formation stage since
the role of MØ in tumour progression has been shown to
occur at the invasion stage of tumour cells where MØ
physically interact with cells invading into the vasculature
[26].
Although an in vivo study examining the effects of whole
body exposure to hypoxia on leukaemia progression
reported no significant differences in blood cell counts or
cellular proliferation or apoptosis rates of the control
mice following daily 18 hour exposure to ~10% oxygen
during 30 days, significantly increased levels of the anti-
angiogenic factor, thrombospondin-1, have been
observed in hypoxia-exposed endothelial cells [60,61].
Therefore, one potential limitation of the current model is
that the whole animal in addition to the tumour was
exposed to cycling hypoxia, which may induce adaptive
physiological responses that might be able to neutralize or
mask changes occurring at the tumour level.
Conclusion
We have demonstrated increased 8-oxo-dG DNA lesions
following exposure to acute cyclic hypoxia (AH), support-
ing the concept that tumour hypoxia could have muta-
genic potential. However, neither this exposure or
treatment with MDA, which caused the greater increase in
8-oxo-dG DNA lesions, affected tumour progression, rais-
ing doubts concerning the importance of oxidative stress
in tumour progression of the MMTV-PyMT model. In this
context, it is of interest that we have obtained similar
results in the MMTV-Neu mammary tumour model (Kal-
liomäki, 2008). Interestingly we also observed that AH
exposure increased TAM content of the PyMT tumours.
This increase was not associated with hypoxic areas in the
tumours nor did it relate to angiogenesis, one of the puta-
tive roles of TAMs. Our current work suggests that this
response may be dependent on changes associated with
the MMTV-PyMT oncogene since similar hypoxia expo-
sure did not significantly increase the F4/80+ MØ content
of the MMTV-Neu tumours (Kalliomäki, 2008).
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